ROS1 Gene Mutation Active Not Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0082893 (ROS1 Gene Mutation)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03049618Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475Treatment